title: Safety of polyethylene glycol recombinant human granulocyte colony-stimulating factor in treating non-small cell lung cancer patients at I b stage.
abstract: OBJECTIVE
  To investigate resistance and safety of HHPG-19K in treating non-small cell lung cancer patients.
  
  
  METHODS
  A total of 30 cases were selected and randomly divided into 5 groups: three HHPG-19K groups of different dosage (60 μg/kg/day, 100 μg/kg/day, 200 μg/kg/day), positive control group (Filgrastim, namely G-CSF5 μg/kg/day) and negative control group. Safety indexes of 5 groups were observed and compared.
  
  
  RESULTS
  All patients had adverse event (100%) in three HHPG-19K groups, and increased ALP, ALT and AST were main events. The degree was mild to moderate. There was no significant difference in the incidence of adverse event between dosage groups and positive control group no difference. But the incidence of negative control group was 13%, which was significantly lower than dosage groups and positive control group.
  
  
  CONCLUSIONS
  non-small cell lung cancer patients have satisfactory tolerance to HHPG-19K, and have no resistance. Besides, dosage at 100 μ g/kg is the most safe.
authors.affiliation: Respiratory Department, Affiliated Chest Hospital of Shanghai Jiaotong University, Shanghai 200030, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Yan
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Fang
authors.initials: F
authors.lastname: Lu
authors.forename: Zhong-Lin
authors.initials: ZL
authors.lastname: Chen
authors.forename: Bao-Hui
authors.initials: BH
authors.lastname: Han
authors.forename: Li-Yan
authors.initials: LY
authors.lastname: Jiang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D043823:Taxoids / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D020011:Protective Agents; D011994:Recombinant Proteins; D043823:Taxoids; D016179:Granulocyte Colony-Stimulating Factor; D000077143:Docetaxel; D011092:Polyethylene Glycols; C423652:pegylated granulocyte colony-stimulating factor; D000069585:Filgrastim; D002945:Cisplatin
keywords: Malaria control; Malaria endemicity; Malaria prevalence; Malaria transmission